Clinical trials: Liver Fibrosis Progression in Chronic Liver Disease
Steatotic Liver Disease, Liver Fibrosis Progression in Chronic Liver Disease
Interventional AI-Human Collaboration for Steatotic Liver Disease Screening
Steatotic liver disease (SLD) is one of the most prevalent chronic liver diseases worldwide, affecting nearly 30% of the global population and projected to exceed 55% by 2040.
- Conditions
- Steatotic Liver Disease, Liver Fibrosis Progression in Chronic Liver Disease, Liver Steatosis, Liver Fibrosis
- Trial name
- NCT07613827
- Testing
- AI-human collaboration for SLD screening
- Where
- China
- Volunteers
- 7,969 people, healthy volunteers welcome
- Sponsor
- Shengjing Hospital
Liver Fibrosis Progression in Chronic Liver Disease
LIVER FIBROSIS PREVALENCE IN FRANCE
"Mortality related to complications of cirrhosis, (hemorrhage, hepatic insufficiency and primary liver cancer) is 15,000 per year in France.
- Trial name
- FIBROFRANCE (NCT01927133)
- Where
- France
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris